FLORENCE, Ky. — Celanese Corp., a global chemical and specialty materials company, on Wednesday announced the expansion of its Northern Kentucky research and development center with the addition of a pharmaceutical drug delivery feasibility lab. The new feasibility lab will drive new development for long-acting controlled release drug delivery.
This represents a significant investment in the pharmaceutical segment of Celanese’s engineered materials business. The feasibility lab expands pharmaceutical companies’ access to highly customized materials and service solutions.
The new Florence pharmaceutical feasibility lab enables Celanese to accelerate customers’ development projects for long-acting delivery of small molecules, biologics and RNA. Services include material characterization; injection molding, hot-melt extrusion, and other prototyping capabilities; monolithic or multi-layer drug-loaded prototypes; in vitro characterization and drug release studies; and tooling design and development.
Celanese offers medical and pharmaceutical material solutions and development support to medical device and pharmaceutical companies worldwide. The company produces differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. Based in Dallas, Celanese employs approximately 7,700 employees worldwide and had 2020 net sales of $5.7 billion.
Click here for more Kentucky business news.